XPG gene rs751402 C>T polymorphism and cancer risk: Evidence from 22 publications
Metrics: PDF 5175 views | HTML 2638 views | ?
Haixia Zhou1,*, Ting-Yan Shi2,*, Wenwen Zhang3,*, Qiwen Li3, Jinhong Zhu4, Jing He1,5 and Jichen Ruan1
1Department of Hematology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027, Zhejiang, China
2Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
3State Key Laboratory of Oncology in South China, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, China
4Molecular Epidemiology Laboratory and Department of Laboratory Medicine, Harbin Medical University Cancer Hospital, Harbin 150040, Heilongjiang, China
5Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong, China
*These authors have contributed equally to this work
Jichen Ruan, email: [email protected]
Jing He, email: [email protected]
Keywords: DNA repair, XPG, polymorphism, cancer susceptibility, meta-analysis
Received: May 12, 2017 Accepted: June 12, 2017 Published: July 18, 2017
The Xeroderma pigmentosum group G (XPG) gene promotes recognition and excision of damaged DNA during the DNA repair process. We conducted a comprehensive search of the MEDLINE, EMBASE, and Chinese Biomedical databases for publications evaluating the association XPG gene rs751402 C>T polymorphism and overall cancer risk. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were adopted to assess the strength of the association. A total of 22 publications encompassing 10538 cases and 10511 control subjects were included in the final meta-analysis. We found the polymorphism to be associated with increased cancer risk (TT vs. CC: OR = 1.18, 95% CI = 1.01–1.38, P = 0.040; CT vs. CC: OR = 1.12, 95% CI = 1.01–1.24, P = 0.040; and CT/TT vs. CC: OR = 1.12, 95% CI = 1.002–1.26, P = 0.045). Stratification by cancer type indicated that this polymorphism may increase the risk of gastric cancer and hepatocellular carcinoma, which was further confirmed by a false-positive report probability analysis. Genotype-based mRNA expression provides further evidence that this polymorphism is associated with altered XPG mRNA expression. This meta-analysis suggests XPG gene rs751402 C>T polymorphism correlates with overall cancer risk, especially for gastric cancer and hepatocellular carcinoma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.